Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

All patients received BIMZELX every four weeks (Q4W) to Week 16, then received either Q4W or Q8W depending upon response to treatment. Receiving Q4W to Week 16, then Q8W thereafter is the approved ...

Belgian drugmaker UCB (Euronext: UCB) today announced new three-year data from Phase III trials, and their open-label ...

Bimzelx is a type of medicine called a monoclonal antibody. Monoclonal antibodies are human-made antibodies created in the lab to mimic antibodies in the body. Bimzelx works by blocking two ...

These medicines act directly on the body’s immune system to help reduce symptoms. In 2023, Bimzelx was approved for the treatment of moderate or severe plaque psoriasis. Clinical studies show ...

1,2,3 BIMZELX received FDA approval for PsA, nr-axSpA, and AS indications in September this year. The research presented at ACR demonstrates the long-term efficacy of BIMZELX, building on the ...

ATLANTA, March 7, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced two-year data from the BE HEARD^ trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe ...

The proportion of patients with severe disease decreased from 87.4% to 20.4%. New data showed that Bimzelx sustained disease control of hidradenitis suppurativa up to 2 years, UCB announced in a ...

UCB SA's solid buy case is driven by Bimzelx's impressive performance and robust financials despite a temporary 19% EBITDA decline due to product launch investments. Bimzelx, approved for ...

The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults. Participants were randomly ...

Dual inhibition with BIMZELX demonstrated high efficacy and sustained clinical benefits across different adult patient populations living with this common inflammatory skin condition.1-4 "A ...

Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with ...